Want to see HK:2289 full AI Analyst Report?
Top Page
Charmacy Pharmaceutical Co., Ltd. Class H
(2289)
Select Model
Select Model
Rating:47Neutral
Price Target:
HK$5.50
▼(-24.76% Downside)
Action:Reiterated
Date:09/30/26
The score is held down primarily by elevated balance-sheet leverage and weakening returns, alongside bearish technical momentum (negative MACD and price below key moving averages). Offsetting factors include strong 2025 free cash flow and a relatively supportive valuation with a high dividend yield, but these do not fully outweigh the financial risk and weak trend.
Positive Factors
Stable Revenue Base
Revenue remained relatively stable and increased 3.33% in 2025 after being roughly flat in 2024. This provides an established sales base and indicates modest ongoing demand, supporting continued operating activity and a foundation for further growth over the next several quarters.
Negative Factors
Rising Balance-Sheet Leverage
Debt increased materially while equity remained fairly flat, pushing debt-to-equity from about 2.74 to 3.39. This indicates that balance-sheet expansion is increasingly debt funded, raising financial risk and reducing flexibility to absorb weaker earnings or fund future needs.
Read all positive and negative factors
Positive Factors
Negative Factors
Stable Revenue Base
Revenue remained relatively stable and increased 3.33% in 2025 after being roughly flat in 2024. This provides an established sales base and indicates modest ongoing demand, supporting continued operating activity and a foundation for further growth over the next several quarters.
Read all positive factors
Charmacy Pharmaceutical Co., Ltd. Class H (2289) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$593.46M
Dividend Yield6.25%
Average Volume (3M)16.00
Price to Earnings (P/E)10.9
Beta (1Y)-0.34
Revenue Growth14.25%
EPS Growth0.83%
CountryHK
Employees827
SectorHealthcare
Sector Strength45
IndustryMedical - Distribution
Share Statistics
EPS (TTM)0.43
Shares Outstanding108,000,000
10 Day Avg. Volume0
30 Day Avg. Volume16
Financial Highlights & Ratios
PEG Ratio-1.24
Price to Book (P/B)1.15
Price to Sales (P/S)0.16
P/FCF Ratio2.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Charmacy Pharmaceutical Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Charmacy Pharmaceutical Co., Ltd. serves as a prominent distributor of pharmaceutical products across the People's Republic of China. The company's comprehensive portfolio includes Western medications, traditional Chinese patent medicines, and var...
Charmacy Pharmaceutical Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
55
Neutral
Balance Sheet
38
Negative
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.68B | 4.38B | 4.44B | 4.40B | 4.18B | 3.79B |
| Gross Profit | 338.93M | 336.01M | 324.76M | 292.74M | 268.61M | 234.12M |
| EBITDA | 153.72M | 152.14M | 155.71M | 136.92M | 121.03M | 107.55M |
| Net Income | 47.11M | 46.27M | 53.28M | 51.34M | 90.47M | 23.15M |
Balance Sheet | ||||||
| Total Assets | 3.93B | 3.96B | 3.46B | 3.25B | 2.87B | 2.76B |
| Cash, Cash Equivalents and Short-Term Investments | 530.00M | 753.92M | 563.15M | 644.76M | 503.81M | 641.76M |
| Total Debt | 2.09B | 2.09B | 1.70B | 1.37B | 1.19B | 1.33B |
| Total Liabilities | 3.32B | 3.35B | 2.84B | 2.65B | 2.27B | 2.26B |
| Stockholders Equity | 606.41M | 616.63M | 618.69M | 597.81M | 594.48M | 504.10M |
Cash Flow | ||||||
| Free Cash Flow | 311.94M | 263.42M | 90.31M | -137.39M | 35.46M | -44.58M |
| Operating Cash Flow | 317.99M | 270.89M | 106.04M | -96.54M | 44.05M | -19.54M |
| Investing Cash Flow | -5.67M | -7.09M | -15.64M | 39.34M | 71.76M | -24.40M |
| Financing Cash Flow | -449.29M | -213.98M | -31.54M | 101.26M | -191.21M | 74.40M |
Charmacy Pharmaceutical Co., Ltd. Class H Technical Analysis
Negative
7.31
Price Trends
5.60
Negative
5.96
Negative
5.86
Negative
Market Momentum
-0.04
Negative
12.72
Positive
104.35
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2289, the sentiment is Negative. The current price of 7.31 is above the 20-day moving average (MA) of 5.50, above the 50-day MA of 5.60, and above the 200-day MA of 5.86, indicating a bearish trend. The MACD of -0.04 indicates Negative momentum. The RSI at 12.72 is Positive, neither overbought nor oversold. The STOCH value of 104.35 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2289.
Charmacy Pharmaceutical Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$4.69B | 12.19 | 7.05% | 4.79% | 6.47% | 8.10% | |
65 Neutral | HK$45.90B | 5.66 | 8.33% | 5.29% | 2.78% | 7.71% | |
61 Neutral | HK$62.83B | 12.57 | 6.21% | 5.97% | 8.02% | -17.74% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | HK$593.46M | 10.91 | 7.70% | 6.25% | 14.25% | 0.83% | |
42 Neutral | HK$648.60M | -7.24 | -2.60% | 17.10% | -2.55% | -145.60% | |
41 Neutral | HK$416.14M | -6.11 | -273.18% | ― | 5.52% | 56.54% |
* Healthcare Sector Average
HK:2289
Charmacy Pharmaceutical Co., Ltd. Class H
5.50
<0.01
0.18%
HK:0673
China Health Group
0.30
-0.20
-40.00%
HK:2607
Shanghai Pharmaceuticals Holding Co
10.94
-0.48
-4.24%
HK:1099
Sinopharm Group Co
14.92
-2.58
-14.74%
HK:1931
IVD Medical Holding Limited
0.40
-9.05
-95.82%
HK:2192
Medlive Technology Co., Ltd.
6.57
-5.66
-46.29%
Charmacy Pharmaceutical Co., Ltd. Class H Corporate Events
Charmacy Pharmaceutical Delivers Double-Digit Revenue Growth in First-Half 2026
Aug 31, 2026
Charmacy Pharmaceutical reported unaudited operating revenue of RMB 2.45 billion for the six months ended 30 June 2026, up 13.6% year on year, with total profit rising 5.9% to RMB 34.6 million. Net profit attributable to shareholders grew 3.8% to ...
Charmacy Pharmaceutical Sets Board Meeting to Review 2026 Interim Results and Dividend
Aug 18, 2026
Charmacy Pharmaceutical Co., Ltd. has scheduled a board meeting for August 31, 2026, to review and approve the interim results for the six months ended June 30, 2026. The board will also consider the declaration and payment of an interim dividend,...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.